Why Levothyroxine Stops Working (The Conversion Problem Nobody Tests)

Most people think of their thyroid as the thing that makes thyroid hormone. And that is true, but it is only part of the story, and the missing part is why so many people on thyroid medication still feel exhausted, cold, foggy, and heavy even when their labs come back perfectly normal.

Here is the full chain before anything else. Your thyroid produces a hormone called T4, which is essentially a storage form, a precursor that your body has not activated yet. T4 circulates in your bloodstream until it reaches tissues in your liver, kidneys, and gut, where enzymes strip one iodine molecule off the molecule and convert it into T3, which is the active form that actually enters your cells and drives metabolism, energy production, and cognitive function. TSH, the test your doctor orders, is produced by your pituitary gland and reflects whether the pituitary thinks T4 levels are adequate. It does not measure what is happening downstream in that conversion step. It does not measure T3.

That chain matters because of how the numbers break down. Your thyroid directly produces only about 20% of the T3 circulating in your body on any given day. The other 80% comes entirely from that peripheral conversion process. So when your doctor prescribes levothyroxine, which is synthetic T4, the medication itself is handling that first 20% replacement. What happens to the other 80% depends entirely on your body's ability to run that conversion, and that is the part that almost never gets tested.

The enzymes that run the conversion are called deiodinases, specifically a class called type 1 and type 2 deiodinases, which are proteins built from selenium. That last part matters because selenium deficiency directly impairs how well these enzymes function, and research in selenium-deficient patients shows that their free T4 levels stay elevated while T3 drops, which is exactly what you would expect when the conversion machinery is not working and T4 is backing up instead of being processed. The ratio of T4 to T3 rises. The person has plenty of raw material but cannot turn it into the finished product.

Now here is where Hashimoto's disease, which is the autoimmune condition behind most hypothyroidism in developed countries, creates a compounding problem. The autoimmune inflammation in Hashimoto's does two things. It damages thyroid tissue, reducing direct T3 production from the gland. And it also downregulates deiodinase activity in peripheral tissues, which means the conversion process slows down at exactly the same time the thyroid is already struggling. Both pathways get hit simultaneously. Replacing T4 with levothyroxine addresses the first problem but does nothing about the second, because the same inflammatory environment that damaged the gland is still suppressing the enzymes needed to activate the medication.

A study looking at levothyroxine-treated patients with normal TSH found that their T3 to T4 ratios were 15 to 20% lower than in the general population, and up to 40% of those patients reported persistent symptoms despite labs that looked completely normal. The TSH was telling the pituitary everything was fine. The T3 was telling a different story in the tissue. Those two things can coexist because TSH is a pituitary signal, not a tissue-level measurement.

There is also a genetic layer that explains why some people simply cannot resolve this through any amount of T4 supplementation. Between 12 and 36% of people carry a variant in a gene called DIO2, which codes for type 2 deiodinase. This variant reduces enzyme activity, meaning carriers are structurally less efficient at converting T4 into T3 regardless of selenium status or inflammation. Research has shown that people with this DIO2 variant report lower psychological well-being at baseline and respond meaningfully better to combination therapy that includes T3 directly rather than relying on conversion. Their bodies are not broken. They just cannot run the conversion process at full capacity, and treating them with T4 only while checking only TSH means that structural limitation is never identified.

Chronic inflammation more broadly, liver dysfunction, and gut dysbiosis can all independently impair conversion as well, because the gut is responsible for a meaningful portion of peripheral T4 to T3 conversion, and the liver is the primary site where type 1 deiodinase operates. Someone with significant gut permeability or liver stress is running the conversion process at a disadvantage before genetics or selenium even enter the picture.

So what does this mean practically. The first step is asking your doctor to test free T3 alongside TSH and free T4, not total T3, because total T3 is bound to proteins and reflects availability rather than active levels. Free T3 tells you whether conversion is actually producing usable hormone. If your TSH is normal but your free T3 is sitting in the lower quarter of the reference range, that gap is the conversion problem in numerical form.

On selenium, the research supports supplementation at around 200 micrograms per day as a way to support deiodinase function, and this is worth raising with your provider given that these enzymes are literally built from selenium and cannot run optimally without it. This is especially relevant if your diet is low in selenium-rich foods like Brazil nuts, seafood, and organ meats.

If selenium and optimization of T4 dosing still leave you symptomatic, and especially if you know or suspect you carry the DIO2 variant, a conversation about combination T4 and T3 therapy or natural desiccated thyroid, which contains both hormones, is a reasonable next step to explore with a provider who understands the conversion pathway.

Levothyroxine is not a flawed medication. It does exactly what it is designed to do. The problem is that it was designed to replace a precursor hormone, and the system that activates it was assumed to be working. For a large number of people, that assumption is wrong, and no one is checking.

---

References

1. Bianco AC, Kim BW. Deiodinases: implications of the local control of thyroid hormone action. J Clin Invest. 2006;11610:2571-2579. PMID: 17016550. Source
2. Endotext NCBI Bookshelf. Thyroid Hormone Synthesis and Secretion: "The thyroid gland produces approximately 20% of total daily T3 production, with the remaining 80% arising from peripheral deiodination of T4." Source
3. Salvatore D, Porcelli T, Ettleson MD, Bianco AC. The relevance of T3 in the management of hypothyroidism. Lancet Diabetes Endocrinol. 2022;10(5):366-372. DOI: 10.1016/S2213-8587(22)00004-3.
4. Peterson SJ, Cappola AR, Castro MR, et al. An online survey of hypothyroid patients demonstrates prominent dissatisfaction. Thyroid. 2019;295:707-721. PMID: 29620972. Source
5. Panicker V, Saravanan P, Vaidya B, et al. Common variation in the DIO2 gene predicts baseline psychological well-being and response to combination thyroxine plus triiodothyronine therapy. JCEM. 2009;945:1623-1629. PMID: 19190113. Source
6. Kobayashi R, Hasegawa Y, Kawaguchi T, et al. Thyroid function in patients with selenium deficiency exhibits high free T4 to T3 ratio. Clin Pediatr Endocrinol. 2021;30(1):19-26. DOI: 10.1297/cpe.30.19.
7. Ventura M, Melo M, Carrilho F. Selenium and thyroid disease: from pathophysiology to treatment. Int J Endocrinol. 2017;2017:1297658. PMID: 28255299. Source

---

Join the free community:
Men: Iron Forge Brotherhood
Women: Powerhouse Fitness